The Pediatric Dermatologist's View of Pediatric Vitiligo.


Journal

Journal of drugs in dermatology : JDD
ISSN: 1545-9616
Titre abrégé: J Drugs Dermatol
Pays: United States
ID NLM: 101160020

Informations de publication

Date de publication:
01 Feb 2024
Historique:
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 2 2 2024
Statut: ppublish

Résumé

No guidelines exist for pediatric vitiligo. To identify practice patterns of pediatric dermatologists treating vitiligo. A PeDRA survey was completed online by 56 pediatric dermatologists. Practitioners reported feeling most comfortable treating 13- to 17-year-olds and least comfortable treating infants. Quality of life was assessed by interview in 89.3%. Topical calcineurin inhibitors (TCIs), topical corticosteroids (TCSs), narrowband UVB, coverup makeup, topical JAK inhibitors (tJAKis), and 308-nm laser were the leading vitiligo therapeutics chosen. 94.5% of practitioners reported experiencing frustration due to difficulties procuring therapies. Pediatric vitiligo has notable effects on quality of life. Some therapeutic options exist which are preferred by pediatric dermatologists. There is a need for more data on therapeutics in infants and young children, J Drugs Dermatol. 2024;23(2): doi:10.36849/JDD.7572e.

Sections du résumé

BACKGROUND BACKGROUND
No guidelines exist for pediatric vitiligo.
OBJECTIVE OBJECTIVE
To identify practice patterns of pediatric dermatologists treating vitiligo.
METHODS METHODS
A PeDRA survey was completed online by 56 pediatric dermatologists.
RESULTS RESULTS
Practitioners reported feeling most comfortable treating 13- to 17-year-olds and least comfortable treating infants. Quality of life was assessed by interview in 89.3%. Topical calcineurin inhibitors (TCIs), topical corticosteroids (TCSs), narrowband UVB, coverup makeup, topical JAK inhibitors (tJAKis), and 308-nm laser were the leading vitiligo therapeutics chosen. 94.5% of practitioners reported experiencing frustration due to difficulties procuring therapies.
CONCLUSION CONCLUSIONS
Pediatric vitiligo has notable effects on quality of life. Some therapeutic options exist which are preferred by pediatric dermatologists. There is a need for more data on therapeutics in infants and young children, J Drugs Dermatol. 2024;23(2): doi:10.36849/JDD.7572e.

Identifiants

pubmed: 38306136
pii: S1545961624P0e77X
doi: 10.36849/JDD.7572
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e77-e78

Auteurs

Classifications MeSH